Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a P...

Полное описание

Библиографические подробности
Главные авторы:	Riste, M, Marshall, JL, Satti, I, Harris, SA, Wilkie, M, Lopez Ramon, R, Wright, D, Wittenberg, RE, Vermaak, S, Powell Doherty, R, Lawrie, A, Conlon, CP, Cosgrove, C, Gleeson, F, Lipman, M, Moss, P, Perrin, F, Dedicoat, M, Bettinson, H, McShane, H
Формат:	Journal article
Язык:	English
Опубликовано:	MDPI 2021

Схожие документы

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
по: Michael Riste, и др.
Опубликовано: (2021-04-01)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
по: Thomas, Z, и др.
Опубликовано: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
по: Tameris, M, и др.
Опубликовано: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
по: Tameris, M, и др.
Опубликовано: (2014)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
по: Mcshane, H
Опубликовано: (2008)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
по: Manjaly Thomas, Z, и др.
Опубликовано: (2019)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
по: Rowland, R, и др.
Опубликовано: (2012)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
по: Michele Tameris, и др.
Опубликовано: (2014-01-01)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
по: Harris, S, и др.
Опубликовано: (2011)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
по: Meyer, J, и др.
Опубликовано: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
по: Meyer, J, и др.
Опубликовано: (2013)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
по: Zita-Rose Manjaly Thomas, и др.
Опубликовано: (2019-04-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
по: Anne Wajja, и др.
Опубликовано: (2017-05-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
по: Wajja, A, и др.
Опубликовано: (2017)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
по: Sander, C, и др.
Опубликовано: (2005)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
по: Minassian, A, и др.
Опубликовано: (2011)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
по: Harris, S, и др.
Опубликовано: (2013)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
по: Odutola, A, и др.
Опубликовано: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
по: Odutola, A, и др.
Опубликовано: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
по: Dieye, T, и др.
Опубликовано: (2013)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
по: Wilkie, M, и др.
Опубликовано: (2019)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
по: Whelan, K, и др.
Опубликовано: (2009)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
по: Pathan, A, и др.
Опубликовано: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
по: Pathan, A, и др.
Опубликовано: (2012)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
по: Owiafe, P, и др.
Опубликовано: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
по: Tandakha N Dieye, и др.
Опубликовано: (2013-01-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
по: Kathryn T. Whelan, и др.
Опубликовано: (2011-01-01)

TB vaccine development: where are we and why is it so difficult?
по: Wilkie, M, и др.
Опубликовано: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
по: Tandakha N. Dieye, и др.
Опубликовано: (2013-01-01)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
по: Minhinnick, A, и др.
Опубликовано: (2016)

Diagnosis of extrapulmonary TB: Experience with the Xpert MTB/Rif assay
по: C.N. Govind, и др.
Опубликовано: (2014-04-01)

Evaluation of Xpert MTB/RIF assay for the diagnosis of paediatric TB
по: F. Ismail, и др.
Опубликовано: (2014-04-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Опубликовано: (2011-01-01)

Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients
по: Raksha Rimal, и др.
Опубликовано: (2022-04-01)

Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.
по: Giovana Rodrigues Pereira, и др.
Опубликовано: (2018-01-01)

Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
по: Neeraj Raizada, и др.
Опубликовано: (2014-01-01)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
по: Mcshane, H, и др.
Опубликовано: (2016)

TB or not TB?
по: Andrew Pirotte, и др.
Опубликовано: (2024-04-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
по: Satti, I, и др.
Опубликовано: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
по: Satti, I, и др.
Опубликовано: (2014)